Community Practice Connections™: Let's Get “Real”: Minimizing Allograft Rejection in Renal Transplantation – Applying the Evidence to Real-World Scenarios

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

Although individuals who receive kidney transplants have high rates of survival—both for themselves and their grafts—at 1 year, clinicians continue to face challenges in preventing rejection and maintaining these outcomes over the long term.
 
This Community Practice Connections™ program provides an in-depth review of some key highlights from a live satellite symposium presented during the American Transplant Congress, which was held in June 2021. This unique and engaging multimedia activity is ideal for the community-based clinician. This program both focuses on the practical aspects of managing kidney transplant candidates and recipients and puts recent clinical trial data into clinical context. It is designed to provide pertinent clinical information for those who did not attend the live event and to help reinforce learnings for those who did.
 

Acknowledgement of Commercial Support

Target Audience

This activity is intended for transplant specialists, transplant surgeons, and nephrologists. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of patients who receive renal grafts will also be invited to participate.
 

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review mechanisms of renal transplant rejection that may offer targets for therapy
• Develop management plans using current and emerging therapies for desensitization of patients undergoing renal transplantation
• Apply strategies to improve adherence to treatment regimens following renal transplantation

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Rita R. Alloway, PharmD
Research Professor
University of Cincinnati College of Medicine
Cincinnati, OH

 

Disclosures: Grant Research Support: Novartis Pharmaceuticals, Amgen, GlaxoSmithKline, Sanofi, Bristol Myers Squibb, Hookipa Pharma, Veloxis Pharmaceuticals, Nobelpharma, AlloVir; Consultant: Veloxis Pharmaceuticals; Speakers’ Bureau: Veloxis Pharmaceuticals, Sanofi.
 

Daniel Brennan, MD
Medical Director, Comprehensive Transplant Center
Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD

 

Disclosures: Grant Research Support: AlloVir, Amplyx Pharmaceuticals, CareDx, Natera; Consultant: CareDx, Hansa Biopharma, Medeor Therapeutics, Sanofi, Veloxis Pharmaceuticals; Speakers’ Bureau: CareDx, Veloxis Pharmaceuticals.
 

E. Steve Woodle, MD, FACS
Director, Solid Organ Transplantation
UC Health
William A. Altemeier Chair in Surgery
Professor of Surgery
Director of Israel Penn International Transplant Tumor Registry
University of Cincinnati College of Medicine
Cincinnati, OH

Disclosures: Grant Research Support: Novartis Pharmaceuticals, Amgen, Bristol Myers Squibb, Veloxis Pharmaceuticals; Consultant: Novartis Pharmaceuticals; Speakers’ Bureau: Sanofi.
 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.